Quick Takeaways
- BlackRock, Inc. filed SCHEDULE 13G/A for Vanda Pharmaceuticals Inc. Common Stock (VNDA).
- Disclosed ownership: 8.1%.
- Date of event: 31 Jan 2025.
BlackRock, Inc. - 31 Jan 2025 SCHEDULE 13G/A Report for Vanda Pharmaceuticals Inc. Common Stock (VNDA)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Symbol
- VNDA
- Shares outstanding
- 58,015,802 shares
- Disclosed Ownership
- 4,699,280 shares
- Ownership
- 8.1%
- Form type
- SCHEDULE 13G/A
- Filing time
- 07 Feb 2025, 13:40:36 UTC
- Date of event
- 31 Jan 2025
- Previous filing
- 05 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BlackRock, Inc. disclosed 8.1% ownership in Vanda Pharmaceuticals Inc. Common Stock (VNDA) on 31 Jan 2025."
What Changed
- Previous schedule filing date: 05 Feb 2025.
- Current filing was accepted on 07 Feb 2025, 13:40.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 8.1% | 4,699,280 | 4,621,714 | 0 | Spencer Fleming | Managing Director |